Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.57 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391105 | 1.00 | GCK (0.57) | GCKP4HTMPTK2AKR1C3AKR1C2 | |
| SCHEMBL18712386 | 0.84 | HCAR3 (0.58) | GCKP4HTMRAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2272468 | 0.84 | P4HTM (0.58) | GCKP4HTMGAARAB9AKDM4E | |
| SCHEMBL2272462 | 0.84 | P4HTM (0.58) | GCKP4HTMGAARAB9AKDM4E | |
| SCHEMBL9000490 | 0.81 | PTK2 (0.53) | PTK2CYP1A2GAARAB9AKDM4E | |
| SCHEMBL14993734 | 0.80 | PTK2 (0.46) | GCKPTK2CYP1A2GAARAB9A | |
| SCHEMBL16229000 | 0.80 | PTK2 (0.46) | GCKPTK2CYP1A2GAARAB9A | |
| SCHEMBL3301252 | 0.80 | PTK2 (0.59) | PTK2CYP1A2GAARAB9AKDM4E | |
| SCHEMBL29882896 | 0.80 | PTK2 (0.59) | PTK2CYP1A2GAARAB9AKDM4E | |
| SCHEMBL20054606 | 0.80 | PTK2 (0.51) | GCKPTK2CYP1A2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882738-B1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-05-31 | — | — | EP | disclosed |
| US-9315522-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-19 | — | — | US | disclosed |
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND US (IE) | 2015-07-30 | — | — | US | disclosed |
| US-9062002-B2 | Substituted pyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| EP-2882738-A1 | NEW ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2014-11-13 | — | — | US | disclosed |
| EP-2785715-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014023814-A1 | NEW ANTIBACTERIAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997028153-A1 | CHINOLINE AND BENZIMIDAZOLE DERIVATIVES AS BRADYKININ AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-07 | — | — | WO | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336153-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | F12, FAR1, NQO2 | GCK 3590/4885P4HTM 1744/4885PTK2 2000/4885 |
| US-20150210719-A1 | ANTIBACTERIAL COMPOUNDS | FAR1, GAA, ECI1 | GCK 1793/4885P4HTM 2694/4885PTK2 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.